While several inhibitors targeting Her2, vascular endothelial growth factor (VEGF), PI3K/mTOR, and EGFR pathways are under investigation for metastatic BC patients, the initial trials investigating their use excluded patients with BCBMs and thus have significantly limited the progress of such strategies for these patients [128]. This evidence concerns the gene VEGFA and breast cancer.